Publications by authors named "Martin L Sos"

48Publications

The next tier of EGFR resistance mutations in lung cancer.

Oncogene 2020 Oct 15. Epub 2020 Oct 15.

Molecular Pathology, Institute of Pathology, University Hospital of Cologne, 50937, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-020-01510-wDOI Listing
October 2020

Family matters: How MYC family oncogenes impact small cell lung cancer.

Cell Cycle 2017 Aug 24;16(16):1489-1498. Epub 2017 Jul 24.

a Molecular Pathology, Institute of Pathology, University of Cologne , Cologne , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2017.1339849DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584863PMC
August 2017

Resistance Mechanisms to AZD9291 and Rociletinib-Response.

Clin Cancer Res 2017 07;23(14):3967-3968

Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0948DOI Listing
July 2017

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

J Thorac Oncol 2015 Jul;10(7):1049-57

*Institute of Pathology, University Hospital of Cologne, Cologne, Germany; †Center for Integrated Oncology Cologne/Bonn, University Hospital of Cologne, Cologne, Germany; ‡Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; §Labor Dr. Quade und Kollegen GmbH, Cologne, Germany; ‖Institute of Human Genetics, University of Cologne, Cologne, Germany; ¶Targos Molecular Pathology GmbH, Kassel, Germany; #Department of Translational Genomics, University of Cologne, Cologne, Germany; **Cologne Center for Genomics, Cologne, Germany; ††GENterprise GENOMICS GmbH, Mainz, Germany; ‡‡Bristol-Myers Squibb R&D, Princeton, New Jersey; §§Evangelische Kliniken Johanniter, Bonn, Germany; ‖‖Malteser Krankenhaus, Lung Cancer Center, Bonn, Germany; ¶¶Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; ##Institute for Hematopathology Hamburg, Hamburg, Germany; and ***New Oncology, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000570DOI Listing
July 2015

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

J Thorac Oncol 2015 Jun;10(6):e40-3

*Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; †Center for Integrated Oncology Köln Bonn, Institute of Pathology, University Hospital of Cologne, Cologne, Germany; ‡Department of Translational Genomics, Center for Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany; §Lung Cancer Group Cologne, Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany; ‖Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany; ¶Center for Integrated Oncology Köln Bonn, Institute of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany; and #Institute of Hematopathology Hamburg, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000503DOI Listing
June 2015

Squamous cell lung cancer: from tumor genomics to cancer therapeutics.

Clin Cancer Res 2015 May;21(10):2236-43

Department of Medicine (Medical Oncology) and Pathology, University of Colorado Denver, Aurora, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862209PMC
May 2015

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.

Cell Rep 2014 Aug 7;8(4):1037-48. Epub 2014 Aug 7.

Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2014.07.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294625PMC
August 2014

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

Nature 2013 Nov 20;503(7477):548-51. Epub 2013 Nov 20.

1] Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, California 94158, USA [2].

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nature12796
Publisher Site
http://dx.doi.org/10.1038/nature12796DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274051PMC
November 2013

Staurosporine-derived inhibitors broaden the scope of analog-sensitive kinase technology.

J Am Chem Soc 2013 Dec 20;135(48):18153-9. Epub 2013 Nov 20.

Howard Hughes Medical Institute and Department of Cellular & Molecular Pharmacology, University of California , San Francisco, California 94143, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ja408704uDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938282PMC
December 2013

A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1.

Cell 2013 Aug;154(4):737-47

Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2013.07.030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950538PMC
August 2013

Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.

J Med Chem 2013 Jul 10;56(14):5757-72. Epub 2013 Jul 10.

Department of Chemistry and Chemical Biology, Technical University of Dortmund, Otto-Hahn-Strasse 6, D-44227 Dortmund, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm4004076DOI Listing
July 2013

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.

Nat Genet 2012 Oct 2;44(10):1104-10. Epub 2012 Sep 2.

Department of Translational Genomics, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.2396DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915822PMC
October 2012

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

Clin Cancer Res 2012 Sep 21;18(17):4682-90. Epub 2012 Aug 21.

Department of Translational Genomics, University of Cologne, c/o MPI for Neurological Research, Gleueler Str. 50, 50931 Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-3260DOI Listing
September 2012

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

Clin Cancer Res 2011 Dec 26;17(23):7394-401. Epub 2011 Sep 26.

Max Planck Institute for Neurological Research, Klaus-Joachim-Zülch Laboratories of the Max Planck Society, Köln, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-1648DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382103PMC
December 2011

Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor.

Bioorg Med Chem 2011 Jan 10;19(1):429-39. Epub 2010 Nov 10.

Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2010.11.007DOI Listing
January 2011

Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling.

PLoS One 2010 Jan 27;5(1):e8919. Epub 2010 Jan 27.

Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Max Planck Society, Köln, Germany.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008919PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811738PMC
January 2010

Systematically linking drug susceptibility to cancer genome aberrations.

Cell Cycle 2009 Nov 27;8(22):3652-6. Epub 2009 Nov 27.

Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Köln, Germany.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/cc.8.22.9936
Publisher Site
http://dx.doi.org/10.4161/cc.8.22.9936DOI Listing
November 2009

Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.

Clin Cancer Res 2005 Nov;11(22):8186-94

Molecular Tumor Biology and Tumor Immunology, Department I for Internal Medicine, Center for Molecular Medicine Cologne, University of Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-0224DOI Listing
November 2005